AR075239A1 - Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso - Google Patents

Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso

Info

Publication number
AR075239A1
AR075239A1 ARP100100305A ARP100100305A AR075239A1 AR 075239 A1 AR075239 A1 AR 075239A1 AR P100100305 A ARP100100305 A AR P100100305A AR P100100305 A ARP100100305 A AR P100100305A AR 075239 A1 AR075239 A1 AR 075239A1
Authority
AR
Argentina
Prior art keywords
inhibitor
growth factor
combination
parp inhibitor
nitro
Prior art date
Application number
ARP100100305A
Other languages
English (en)
Original Assignee
Bipar Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc
Publication of AR075239A1 publication Critical patent/AR075239A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica que comprende por lo menos un inhibidor de la PARP en combinacion con por lo menos un inhibidor de un factor de crecimiento, donde dicho inhibidor de la PARP es de la formula (1), o un metabolito del mismo en la cual R1, R2, R3, R4 y R5 son independientemente seleccionados del grupo que consiste en hidrogeno, hidroxi, amino, nitro, nitroso, yodo, alquilo C1-6, alcoxi C1-6, cicloalquilo C3-7 y fenilo, donde por lo menos dos de los cinco sustituyentes R1, R2, R3, R4 y R5 son siempre hidrogeno, por lo menos uno de los cinco sustituyentes son siempre nitro y por lo menos un sustituyente situado adyacente a un nitro es siempre yodo, o una sal, solvato, isomero o tautomero del mismo y donde el inhibidor del factor de crecimiento es seleccionado del grupo que consiste en AEE788, GW-974, BIBW 2992, catumaxomab, vacuna EGF, icotinib, leflunomida, necitumumab, neratinib, pertuzumab, PF-299804, zalutumumab, CNTF, tanezumab, dalotuzumab, AMG-479, rilotumumab, lanreotida, OSI 906, pasireotide, PF-2341066, MetMab, XL-184, aflibercept, apatinib, BIBF-1120, PAM-1, XL-999, brivanib, fluocinolona, midostaurina, motesanib, OTS-102, OSI-632, vatalanib, pazopanib, BMS-690514, ramucirumab, ridoforolimus, tivozanib, alacizumab pegol, PD173074, PHA 665752, DMQ, SU4312, K252a, X-647, VEGF-Trap-Eye, pirfenidona, masitinib y nilotinib. Reivindicacion 3: El uso de la composicion de acuerdo con la reivindicacion 1 para la elaboracion de un medicamento para el tratamiento del cáncer de pulmon. Reivindicacion 5: El uso de acuerdo con la reivindicacion 3 o 4, en el cual se obtiene por lo menos un efecto terapéutico, donde dicho por lo menos un efecto terapéutico es la reduccion del tamano de un tumor pulmonar, la reduccion de metástasis, la remision total, remision parcial, la estabilidad de la enfermedad o una respuesta patologica completa. Reivindicacion 27: El uso de acuerdo con la reivindicacion 3 u 8, que además comprende administrar al paciente uno o más del grupo que consiste en una ciclodextrina, un tensioactivo, y un cosolvente en combinacion con el inhibidor de la PARP.
ARP100100305A 2009-02-04 2010-02-04 Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso AR075239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14997709P 2009-02-04 2009-02-04

Publications (1)

Publication Number Publication Date
AR075239A1 true AR075239A1 (es) 2011-03-16

Family

ID=42542374

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100305A AR075239A1 (es) 2009-02-04 2010-02-04 Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso

Country Status (14)

Country Link
US (1) US20120130144A1 (es)
EP (1) EP2393364A4 (es)
JP (1) JP2012516895A (es)
KR (1) KR20110113648A (es)
CN (1) CN102307475A (es)
AR (1) AR075239A1 (es)
AU (1) AU2010210636A1 (es)
CA (1) CA2751397A1 (es)
IL (1) IL214366A0 (es)
MX (1) MX2011008221A (es)
RU (1) RU2011136641A (es)
SG (1) SG173198A1 (es)
TW (1) TW201032796A (es)
WO (1) WO2010091140A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C2 (ru) 2005-02-03 2010-12-10 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8143447B2 (en) 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
MX365008B (es) 2008-06-17 2019-05-20 Wyeth Llc Combinaciones antineoplasticas que contienen hki-272 y vinorelbina.
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
ES2561495T3 (es) 2009-04-06 2016-02-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra cáncer de mama
FI20115640A0 (fi) 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
US20150182490A1 (en) * 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
JP6393682B2 (ja) 2012-07-13 2018-09-19 トゥルン イリオピスト 併用療法ｉｉｉ
WO2014170441A1 (en) * 2013-04-19 2014-10-23 Dna Therapeutics Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules
WO2016054055A1 (en) * 2014-09-29 2016-04-07 Board Of Regent, The University Of Texas System Prediction of response to parp inhibitors and combinational therapy targeting c-met and parp1
EP3253211A4 (en) * 2015-02-05 2018-10-31 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
PT3325623T (pt) 2015-07-23 2019-09-04 Inst Curie Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro
MX2018005071A (es) * 2015-10-26 2018-11-29 Medivation Tech Llc Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
EP4071174A1 (en) * 2016-02-15 2022-10-12 AstraZeneca AB Methods comprising fixed intermittent dosing of cediranib
EP3549608A4 (en) * 2016-12-01 2020-08-12 Jiangsu Hengrui Medicine Co., Ltd. USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER
CN106906184B (zh) * 2017-02-27 2021-04-23 广东昭泰体内生物医药科技有限公司 一种促进肺癌细胞生长的方法
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
BR112019024135A2 (pt) 2017-05-18 2020-06-02 Tesaro, Inc. Terapias de combinação para o tratamento de câncer
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. METHOD OF TREATMENT OF GLIOBLASTOMA
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
WO2019067978A1 (en) * 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
BR112020010435A2 (pt) * 2017-12-06 2020-11-24 Jiangsu Hengrui Medicine Co., Ltd. uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia
JP2021515580A (ja) 2018-03-13 2021-06-24 オンクセオＯｎｘｅｏ がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
JP7372253B2 (ja) 2018-04-05 2023-10-31 ノビガ・リサーチ・エービー 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
TW202110448A (zh) * 2019-05-28 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN110917199A (zh) * 2019-11-22 2020-03-27 上海市肺科医院 一种小分子化合物在制备肺癌化疗增敏药物中的应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114292895A (zh) * 2022-02-10 2022-04-08 上海交通大学医学院附属第九人民医院 检测对parp抑制剂耐受的物质在制备评估肺癌患者对质子放疗敏感性的产品中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287120A1 (en) * 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
JPWO2002055076A1 (ja) * 2001-01-04 2004-05-13 第一製薬株式会社 シクロデキストリン製剤
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
KR101591656B1 (ko) * 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸

Also Published As

Publication number Publication date
US20120130144A1 (en) 2012-05-24
MX2011008221A (es) 2011-08-17
CN102307475A (zh) 2012-01-04
TW201032796A (en) 2010-09-16
SG173198A1 (en) 2011-09-29
IL214366A0 (en) 2011-09-27
AU2010210636A1 (en) 2011-09-22
EP2393364A1 (en) 2011-12-14
CA2751397A1 (en) 2010-08-12
RU2011136641A (ru) 2013-03-10
JP2012516895A (ja) 2012-07-26
KR20110113648A (ko) 2011-10-17
WO2010091140A1 (en) 2010-08-12
EP2393364A4 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
AR075239A1 (es) Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
AR094654A1 (es) Modulador del receptor de andrógeno y sus usos, método para tratamiento, composición farmacéutica
ECSP12012004A (es) Método de tratamiento de la fibrilación auricular
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
JP2012516895A5 (ja) 成長因子阻害剤と組み合わせた４−ヨード−３−ニトロベンズアミドによる肺がんの治療
ES2762250T3 (es) Tratamiento combinado del cáncer
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
RU2013156378A (ru) 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы
NZ723271A (en) Fused imidazole derivatives useful as ido inhibitors
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
CY1115245T1 (el) Φαρμακευτικη συνθεση που συνδυαζει διαφορους φλεβοτονικους και αγγειοπροστατευτικους παραγοντες για τη θεραπεια χρονιας φλεβικης ανεπαρκειας
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
US20120208883A1 (en) Treatment of oncological diseases
JP2013511526A5 (es)
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
Chen et al. Hydroxygenkwanin inhibits class I HDAC expression and synergistically enhances the antitumor activity of sorafenib in liver cancer cells
WO2012105610A1 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
CA2577550C (en) Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
KR20180125967A (ko) 암 치료용 pic 포함 조성물
RU2015124954A (ru) Фармацевтические комбинации
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
Ogata et al. Severe aplastic anemia during osimertinib therapy in a patient with egfr tyrosine kinase inhibitor–resistant non–small cell lung cancer
Danciulescu et al. Temozolomide and targeted therapy against epidermal growth factor receptor in glioma

Legal Events

Date Code Title Description
FB Suspension of granting procedure